DDInter1217 DDInter1763
Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body. Miglitol should be taken at the start of a meal for maximal effect and the effect will depend on the amount of poly and oligosaccharides in the diet. Miglitol inhibits alpha-glucosidase, making less sugars available for digestion and reducing postprandial hyperglycemia. Unlike other drugs of the same class, miglitol is not metabolized and the unmetabolized drug is excreted by the kidneys.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Miglitol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Miglitol {u} (Compound) causes {v} (Side Effect) Intestinal perforation
Intestinal perforation {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Miglitol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Miglitol {u} (Compound) causes {v} (Side Effect) Abdominal pain
Abdominal pain {u} (Side Effect) is caused by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Miglitol {u} (Compound) resembles {v} (Compound) Miglustat
Miglustat {u} (Compound) causes {v} (Side Effect) Nervous system disorder
Nervous system disorder {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Miglitol {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is associated with {v} (Gene) PPP2CA
PPP2CA {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Miglitol {u} (Compound) binds {v} (Gene) GANAB
GANAB {u} (Gene) interacts with {v} (Gene) MYC
MYC {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Miglitol {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is associated with {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Miglitol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Miglitol {u} (Compound) binds {v} (Gene) AMY2A
AMY2A {u} (Gene) interacts with {v} (Gene) TRIAP1
TRIAP1 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Miglitol (Compound) causes Intestinal perforation (Side Effect) and Intestinal perforation (Side Effect) is caused by Temsirolimus (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Miglitol (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Miglitol (Compound) resembles Miglustat (Compound) and Miglustat (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Temsirolimus (Compound)
Miglitol (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is associated with PPP2CA (Gene) and PPP2CA (Gene) is downregulated by Temsirolimus (Compound)
Miglitol (Compound) binds GANAB (Gene) and GANAB (Gene) interacts with MYC (Gene) and MYC (Gene) is upregulated by Temsirolimus (Compound)
Miglitol (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is associated with CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Miglitol (Compound) binds AMY2A (Gene) and AMY2A (Gene) interacts with TRIAP1 (Gene) and TRIAP1 (Gene) is downregulated by Temsirolimus (Compound)